

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SCHIMMEL PAUL (Last) (First) (Middle) C/O ATYR PHARMA, INC. 3545 JOHN HOPKINS COURT, SUITE #250 (Street) SAN DIEGO CA 92121 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol aTYR PHARMA INC [LIFE]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/12/2015	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								12,572	D	
Common Stock	05/12/2015		C		31,181	A	(1)	31,181 ⁽²⁾	I	See Footnote ⁽³⁾
Common Stock	05/12/2015		C		470,020	A	(1)	600,015 ⁽²⁾	I	See Footnote ⁽⁴⁾
Common Stock	05/12/2015		C		46,152	A	(5)	646,167 ⁽⁶⁾	I	See Footnote ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series D Redeemable Convertible Preferred Stock	(1)	05/12/2015		C			248,024	(1)	(1)	Common Stock	31,181 ⁽²⁾	\$0.00	0	I	See Footnote ⁽³⁾
Series A Redeemable Convertible Preferred Stock	(1)	05/12/2015		C			525,000	(1)	(1)	Common Stock	66,004 ⁽²⁾	\$0.00	0	I	See Footnote ⁽⁴⁾
Series B Redeemable Convertible Preferred Stock	(1)	05/12/2015		C			1,200,000	(1)	(1)	Common Stock	150,865 ⁽²⁾	\$0.00	0	I	See Footnote ⁽⁴⁾
Series B-2 Redeemable Convertible Preferred Stock	(1)	05/12/2015		C			1,440,058	(1)	(1)	Common Stock	181,046 ⁽²⁾	\$0.00	0	I	See Footnote ⁽⁴⁾
Series C Redeemable Convertible Preferred Stock	(1)	05/12/2015		C			558,508	(1)	(1)	Common Stock	70,216 ⁽²⁾	\$0.00	0	I	See Footnote ⁽⁴⁾
Series D Redeemable Convertible Preferred Stock	(1)	05/12/2015		C			15,031	(1)	(1)	Common Stock	1,889 ⁽²⁾	\$0.00	0	I	See Footnote ⁽⁴⁾
Series E Redeemable Convertible Preferred Stock	(3)	05/12/2015		C			446,827	(5)	(5)	Common Stock	46,152 ⁽⁶⁾	\$0.00	0	I	See Footnote ⁽⁴⁾

Explanation of Responses:

- The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Person converted into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. These shares converted into Common Stock on a 1-for-7.95413 basis.
- Reflects a 1-for-7.95413 stock conversion of the Issuer's Preferred Stock into Common Stock which became effective immediately prior to the closing of the Issuer's initial public offering.

